Drug recalls aren’t unusual, and we’ve recently seen quite a few of those. When manufacturers discover issues with certain products, like incorrect dosage, they recall the medicine to prevent it from harming patients. But this is the first time we have seen a top COVID-19 drug recall. Gilead’s Veklury, better known as remdesivir, was the …
The drug formerly known as remdesivir and now being marketed as Veklury is the first FDA-approved coronavirus treatment. It was also among the drugs used to treat President Trump during his recent bout of COVID-19. However, not everyone thinks the drug is a winner or will actually work all the time against COVID-19. The World …
The World Health Organization’s massive Solidarity study of COVID-19 therapies has been finalized, revealing that the promising coronavirus cure remdesivir can’t save lives. The WHO research also showed that none of the other drugs tested during the Solidarity trial can prevent COVID-19 deaths. Solidarity studied remdesivir, hydroxychloroquine, lopinavir, ritonavir, interferon, and combinations thereof. Remdesivir was …
Eli Lilly is seeking emergency authorization approval for a promising coronavirus drug that was found to be an effective COVID-19 therapy. The company has several ongoing clinical trials for its monoclonal antibody drug, including one where the LY-CoV555 compound has been combined with another promising COVID-19 drug called remdesivir. Eli Lilly announced that the clinical …
Remdesivir is one of the novel coronavirus treatments that has shown some efficacy, but the drug is already in short supply. The Trump administration purchased nearly the entire remdesivir supply that Gilead Science will manufacture over the next three months. The US government purchased 500,000 doses of remdesivir, much to the dismay of critics from …
Experimental coronavirus drug remdesivir is effective in mild to moderate COVID-19 cases, according to recent research. Remdesivir can’t prevent complications or reduce mortality, but Gilead thinks that administering the therapy earlier to confirmed patients could improve the results. The drugmaker will use remdesivir inside a nebulizer in a clinical test to speed up access to …
The only effective coronavirus treatment approved for standard care so far will run out at the end of this month, the US government said. Our supply of remdesivir is expected to be depleted by June 29th, and Gilead likely won’t be able to deliver more until this summer, as manufacturing efforts increase. Gilead plans to …
Data from a new coronavirus drug trial shows that a 5-day course of remdesivir therapy is more effective than standard care, and works just as well as a 10-day course. The results only apply to a specific set of COVID-19 patients, namely people who developed a moderate case, which included pneumonia without reduced oxygen levels. …
Coronavirus drug remdesivir was called the standard of care for COVID-19 patients in late April when Dr. Anthony Fauci announced the early results of an extensive study. Fauci said the drug can speed up recovery, although the COVID-19 treatment did not affect mortality. The drug should be combined with other therapies in a future study. …
Coronavirus treatments have been hard to come by, but researchers are hopeful that combining the antiviral drug remdesivir with a powerful anti-inflammatory could be effective. Remdesivir stops the virus from multiplying, while an anti-inflammatory calms the immune system. Dr. Aneesh Mehta of Emory University refers to the combination as a “one-two punch.” Visit BGR’s homepage …
